A novel cell model targeted on GLP-1 receptor for application to anti-diabetic candidates screening

Yaoxue Xuebao

Volumn 44, Issue 3, 2009, Pages 309-313

  Huan, Yi ^a   Shen, Zhu Fang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cell model; Diabetes; GLP 1 receptor agonist; High throughput drug screening

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; EXENDIN 9-39; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; DRUG INHIBITION; DRUG TARGETING; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PANCREAS ISLET CELL; PLASMID; REPORTER GENE;

ANIMALS; CELL LINE; CYCLIC AMP RESPONSE ELEMENT MODULATOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; ISOQUINOLINES; PEPTIDE FRAGMENTS; PEPTIDES; PLASMIDS; RATS; RECEPTORS, GLUCAGON; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSFECTION; VENOMS;

EID: 67249100447     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight [J]. mt J Clin Pract Suppl, 2007, (154): 19-28.
2. Standi E. The importance of beta-cell management in type 2 diabetes [J]. mt J Clin Pract Suppl, 2007, (153): 10-19.
3. Nelson F, Poon T, Guan X, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes [JJ. Diabetes Technol Ther, 2007,9: 3 17-326.
4. Chen D, Liao J, Li N, et al. A nonpeptidic agonist of glucagonlike peptide I receptors with efficacy in diabetic db/db mice [I]. Proc NatI Acad Sci USA, 2007, 16, 104: 943-948.
5. Choy M, Lam S. Sitagliptin: a novel drug for the treatment of type 2 diabetes [J]. Cardiol Rev, 2007, 15: 264-271.
6. Raun K, von Voss F, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide- 1 analog, minimizes food intake in severely obese minipigs [J]. Obesity (Silver Spring), 2007, 15: 1710-1716.
7. Tiessen RQ Castaigne JP, Drevfus JF, et al. Phannacokinetics and tolerability of a novel long-acting glucagon-like peptide- 1 analog, CJC-1131, in healthy and diabetic subjects [J]. mt J Clin Pharrnacol Ther, 2008, 46: 443-452.
8. Granata R, Settanni F, Gallo D, et al. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function [J]. Diabetes, 2008, 57: 967-979.
9. Skoglund C3 Hussain MA, HuLz GG Glucagon-like peptide I stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element [J]. Diabetes, 2000,49: 1156-1164.
10. Parkes DG Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and ifl vitro [J]. Metabolism, 2001, 50: 583-589.
11. Chepurny OG Hussain MA, Holz GG. Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220 [J]. Endocrinology, 2002, 143: 2303-2313.
12. Islam D, Zhang N, Wang P, et al. Epac is involved in cAMP-stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic alpha and intestinal L cell lines [J]. Am J Physiol Endocrinol Metab, 2009, 296: E174-l 81.
13. Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release [J]. Endocrinology, 2007, 148: 2601-2609.
14. Zhao XX, Gao R, Li FR. High through-put drug screening based on the cell model [J]. Pharm Biotechnol (lJ(/44p4), 2008, 15: 227-230.
15. Guo F, Liu YX, Zheng DX, et al. Establishment of high through-put drug screening model targeting retinoic acid receptor in cells [J]. Acta Pharm Sin 2005,40: 908-911.
16. Huang M, Rung Y, Ning HX, et al. Establishment of high through-put drug screening cell models based on JAK-STAT signal pathway [J], Acta Phann Sin (lJii), 2004, 39: 164-167.
17. Chepurny OQ Holz GG. A novel cyclic adenosine mono- phosphate responsive luciferase reporter incorporating a nonpalindromic cyclic adenosine monophosphate response element provides optimal performance for use in G protein coupled receptor drug discovery efforts [J]. J Biomol Screen, 2007, 12: 740-746.